Yatharth Q2FY27: consolidated revenue +54% YoY, margin compression caps PAT at +17%
PAT +17.47% YoY · revenue +54.4% · margins compressing
₹431.42 Cr
+54.4% YoY
₹48.46 Cr
+17.47% YoY
11.1%
-3.2pp YoY
₹5.25
Consolidated revenue for Q2 FY27 rose 54.4% YoY (and 9.9% QoQ) to ₹431.42 Cr, continuing the pace set in Q1 FY27 (+52.3% YoY) and running well ahead of management's guidance to outgrow FY26's 36% full-year growth. Consolidated PAT grew a slower 17.5% YoY to ₹48.46 Cr, with profit attributable to owners at ₹50.59 Cr (EPS ₹5.25, +22.7% YoY) — the gap between the two PAT figures stems from a ₹2.13 Cr quarterly loss at minority-held new-hospital subsidiaries (five such units reported a combined ₹4.19 Cr net loss this quarter per the auditors' note), a loss borne by minority shareholders rather than the parent.
Q2 FY-2027 vs prior quarters
Net profit margin compressed to 11.10% from 14.28% a year earlier, even as operating margin (EBITDA/revenue) held roughly flat at 23.65% versus 23.09% YoY — the squeeze sits below the EBITDA line. Finance costs jumped to ₹8.28 Cr from just ₹0.26 Cr a year ago, and depreciation rose 75% YoY to ₹33.14 Cr, both tracking the capex behind new hospitals (consolidated borrowings rose to ₹450.69 Cr from ₹253.33 Cr at FY26-end, with gross block and CWIP at ₹9,513 Cr and ₹2,421 Cr respectively). Management had flagged this dynamic on the prior call: new hospitals are only expected to reach 25-27% EBITDA margins by FY28-29, and this quarter's 23.65% OPM, though better than Q1's 23.35%, still sits under the company's stated ">24%" floor.
The stock went into the print at ₹945.8, down 8.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 4 consecutive quarters; revenue is at a 6-quarter high.
FY27 revenue growth to surpass FY26's 36% YoY growth (Q1 achieved 52.3% YoY). EBITDA margin maintained at upwards of 24%, but Q1 at 23.3%. ARPOB expected to grow 9-10% YoY; new hospitals targeting 25-27% EBITDA margins by FY28-29.
— This quarter: met
Against the prior concall's confident, optimistic tone and the guidance to outgrow FY26's 36% revenue growth, this quarter's 54% YoY print clearly beats the topline promise, while the margin commitment is not yet met but is trending the right way sequentially. No Q2 FY27-specific street estimates for this company turned up in a search for brokerage previews, so vsStreet is unknown; FY27 full-year consensus (per analyst trackers) pegs revenue near ₹1,700 Cr (+41% YoY), a bar this quarter's run-rate is tracking ahead of. Standalone PAT was ₹37.06 Cr on standalone revenue of ₹194.91 Cr — under half of consolidated revenue — underscoring that a growing share of both growth and margin drag now sits inside subsidiaries rather than the parent entity.
W1
Whether OPM clears management's >24% floor (currently 23.65%, vs 23.35% in Q1 FY27).
W2
Trajectory of finance costs (₹8.28 Cr this quarter vs ₹0.26 Cr YoY) and depreciation (₹33.14 Cr, +75% YoY) as new-hospital capex matures.
W3
Regulatory approval status of the Advent International (via Rasmalai Limited) 24.9% preferential stake acquisition approved at the Oct 15, 2026 EGM.
Informational and educational content only. Not investment advice.